Latest Property Portfolio News

Page 11 of 24
Memphasys Limited is intensifying its commercial push for Felix, an innovative automated sperm separation system for IVF, backed by a landmark Middle East partnership and a fresh capital raise to scale manufacturing and sales.
Ada Torres
Ada Torres
25 Sept 2025
Hazer Group has been granted a pivotal patent in Singapore for its proprietary graphite morphology process, reinforcing its foothold in Southeast Asia's clean energy and advanced manufacturing markets.
Maxwell Dee
Maxwell Dee
23 Sept 2025
CAQ Holdings Limited reported a 29.6% revenue decline and a 43.9% increase in net loss for the half-year ended June 2025, driven largely by falling investment property values and ongoing liquidity challenges.
Eva Park
Eva Park
22 Sept 2025
Desane Group Holdings has sold its commercial property at 13 Sirius Road, Lane Cove for $8.7 million, marking a strategic shift to fund future growth opportunities.
Eva Park
Eva Park
4 Sept 2025
Mesoblast has entered agreements to issue up to US$50 million in convertible notes, aiming to strengthen its capital base and support pipeline growth, pending shareholder approval.
Ada Torres
Ada Torres
4 Sept 2025
4DS Memory Limited posted a $9.68 million loss for FY2025 as it advanced its 20nm ReRAM technology, encountering manufacturing setbacks that prompted a detailed root cause analysis. The company secured $8 million in capital to support ongoing development and strategic partnerships.
Sophie Babbage
Sophie Babbage
29 Aug 2025
Chimeric Therapeutics reported a reduced net loss of $10.43 million for FY2025, driven by cost efficiencies and strategic project reprioritisation, while making significant clinical progress in its CAR T-cell and NK cell therapy programs.
Ada Torres
Ada Torres
29 Aug 2025
Patrys Limited reported a 14.9% reduction in net loss for FY2025, driven by lower R&D expenses and tax incentives, while impairing key PAT-DX1 assets and shifting focus to PAT-DX3 development.
Ada Torres
Ada Torres
29 Aug 2025
Zelira Therapeutics reported a significantly reduced loss of AUD 3.85 million for FY25, driven by clinical progress and strategic funding for its HOPE® cannabinoid medicines. The company also expanded its patent portfolio and commercial footprint across key markets.
Ada Torres
Ada Torres
29 Aug 2025
DGL Group reported a modest revenue rise but faced a significant earnings dip in FY25, driven by losses in its Environmental division and restructuring costs. The company is now focusing on integration and operational efficiencies to rebound in FY26.
Victor Sage
Victor Sage
29 Aug 2025
Alterity Therapeutics reported a reduced net loss of A$12.15 million for FY2025, buoyed by positive Phase 2 clinical trial results for its lead drug ATH434 in Multiple System Atrophy and a successful A$40 million capital raising.
Ada Torres
Ada Torres
29 Aug 2025
BCAL Diagnostics has launched its first commercial breast cancer diagnostic test, BREASTESTplus™, in Australia, marking a key milestone despite a $7.24 million loss for FY2025. The company is also advancing its US operations with a new subsidiary and clinical trials underway.
Ada Torres
Ada Torres
29 Aug 2025